Search results

21 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
LCCC.jpg
Lab Operations and Automation Manager Chatura Jayakody operates the liquid handler in the Center for Integrative Chemical Biology and Drug Discovery in Marsico Hall at the University of North Carolina at Chapel Hill.
Located in Images / Faculty & Staff
Advances in melanoma treatment focus of UNC conference
At the 10th Annual UNC Conference on Melanoma and Complex Skin Cancers: A Multidisciplinary Perspective, experts in melanoma treatment presented advances in treating the disease on Thursday. The conference, held at the William and Ida Friday Center for Continuing Education, drew dermatologists, surgeons, medical oncologists and other health care providers to hear presentations on topics ranging from immunotherapy drugs and targeted treatments for metastatic disease, radiation strategies, and chemotherapy to prevent skin cancer.
Located in News
blossom-next.jpg
Blossom Damania, PhD, Assistant Dean for Research, professor of microbiology and immunology at the UNC School of Medicine and a member of UNC Lineberger Comprehensive Cancer Center.
Located in landing / / Images / 2016
Device hits pancreatic tumors hard with toxic four-drug cocktail, sparing the body
A new implantable device delivers first-line treatment for pancreatic cancer directly to tumors, bypassing bloodstream and limiting widespread side effects. A team of researchers from the University of North Carolina including Drs. Jen Jen Yeh and Joseph DeSimone, has shown in preclinical research that the device can deliver a particularly toxic dose of drugs directly to pancreatic tumors to stunt their growth or, in some cases, shrink them. This approach would also spare the patient toxic side effects.
Located in News
Low-risk prostate cancer best managed with active surveillance
UNC Lineberger researcher Dr. Ronald C. Chen was first-author of a report published in the Journal of Clinical Oncology that details guidelines for the active surveillance of men with low-risk prostate cancer. The guidelines, originally authored by Cancer Care Ontario, were reviewed and endorsed by the American Society of Clinical Oncology.
Located in News
Nanoparticle form of bone loss prevention drug effective against cancer, preclinical study finds
A preclinical study led by a UNC Lineberger researcher found that a nanoparticle form of a drug used to prevent bone loss was effective against small-cell lung and prostate cancer cells. The results were published in the journal Biomaterials.
Located in News
New compound is effective against drug-resistant leukemia, preclinical study finds
Researchers at UNC Lineberger and at other institutions developed a new potential treatment for acute myeloid leukemia. In the journal JCI Insight, they report that the compound MRX-2843 more than doubled the median days of survival in laboratory models with a drug-resistant form of the disease.
Located in News
Online e-cigarette searches number in the millions, but few focus on vaping health risk or quitting smoking
A study published recently in the American Journal of Preventive Medicine found that Google searches about electronic cigarettes were more commonly related to shopping for e-cigarettes, while quitting smoking represented less than 1 percent of e-cigarette searches in each of 2013 and in 2014. The study’s senior author was Rebecca S. Williams, MHS, PhD, a UNC Lineberger member.
Located in News
Physicians issue advice, raise questions about best practices for evaluating blood in the urine as a sign of cancer
A new report from the American College of Physicians’ High Value Care Task Force issues advice for physicians on how to detect and evaluate blood found in the urine, which is known as hematuria. The report, which was first-authored by UNC Lineberger Comprehensive Cancer Center member Dr. Matthew Nielsen, also raises questions about the potential harms associated with diagnostic tests that are commonly employed to evaluate this condition.
Located in News
Preclinical study finds no benefit for diabetes drug in pancreatic cancer
UNC Lineberger researchers found in a study published in PLOS ONE that the diabetes drug metformin failed to show any benefit against pancreatic cancer, despite excitement about the drug for potential anti-cancer benefits. They believe the study shows the importance of testing new therapies in preclinical animal models that incorporate actual tumor tissue to better predict patient response.
Located in News